Supplementary Table e-2. Demographic and clinical characteristic considering genders (A) and Riluzole treatment (B) in the London and Oxford

cohorts separately and combined.

A. Gender	London		Oxford		Combined	
	Male (n=67)	Female (n=36)	Male (n=45)	Female (n=19)	Male (n=112)	Female (n=55)
Blood NfL level^ (pg/mL)	82.3 (46.5, 150)	142.9 (76.1, 218.8)**	90 (53, 146)	90 (59, 183)	84.9 (50.8, 146.3)	125.7 (62, 214.7)*
Age At Sampling^ (years)	63.6 (57.8, 68.3)	69.7 (59.3, 74.2)*	63 (53.5, 69)	57 (54, 67)	63.3 (55.2, 69)	67 (55.3, 73)
Age At Onset^ (years)	61.9 (44, 66.1)	67.7 (57.8, 73.8)**	60.8 (51.1, 67.7)	54.8 (51.2, 65.7)	61.7 (51.1, 66.5)	65.7 (53.2, 70.9)#
PRB^ (points/month)	0.449 (0.156, 0.853)	0.684 (0.362, 1.471)**	0.470 (0.232, 0.900)	0.449 (0.275, 0.753)	0.452 (0.181, 0.855)	0.593 (0.313, 1.175)*
PRL^ (points/month)	0.521 (0.202, 0.893)	0.770 (0.407, 1.326)*	0.523 (0.226, 0.963)	0.449 (0.272, 1.067)	0.522 (0.210, 0.925)	0.705 (0.354, 1.175)*
ALSFRS_R Score^	39 (33, 44)	33.5 (26.3, 37.8)***	35 (31, 39)	36 (32, 37)	38 (32, 42)	35 (28, 37)***
Diagnosis [n (%)]						
Definite ALS	13 (19.4%)	6 (16.7%)	13 (28.9%)	7 (36.8%)	26 (23.2%)	13 (23.6%)
Probable ALS	26 (38.8%)	21 (58.3%)	14 (31.1%)	7 (36.8%)	40 (35.7%)	28 (50.9%)
Possible ALS	21 (31.3%)	6 (16.7%)	18 (40%)	5 (26.4%)	39 (34.8%)	11 (20%)
Lab-Supported probable ALS	7 (10.5%)	3 (8.3%)	0	0	7 (6.3%)	3 (5.5%)
B. Use of Riluzole	London		Oxford		Combined	

	No (n=29; M/F: 21/8)	Yes (n=74; M/F: 46/28)	No (n=34; M/F: 24/10)	Yes (n=30; M/F: 21/9)	No (n=63; M/F: 45/18)	Yes (n=104; M/FL 67/37)
Blood NfL level^ (pg/mL)	66.8 (37.5, 139.2)	114 (58.7, 178.8)##	98.5 (50.3, 155.3)	88.5 (57.5, 135.5)	83 (42, 151)	99.9 (59, 158.6)
Age At Sampling^ (years)	64.4 (58.2, 69.9)	66.1 (58.7, 72.5)	66.5 (60.3, 70.8)	56 (51.5, 65.3)**	65.5 (58.6, 70)	63.8 (54, 69.8)
Age At Onset^ (years)	62.2 (54, 67.6)	64.7 (56.5, 70.1)	63.6 (56.3, 68.9)	53.6 (50.0, 62.3)**	62.9 (54.4, 68.6)	61.8 (51.2, 67.9)
PRB^ (points/month)	0.516 (0.127, 0.784)	0.513 (0.246, 1.017)	0.402 (.0220, 0.838)	0.516 (0.321, 0.801)	0.410 (0.169, 0.785)	0.516 (0.267, 0.914)
PRL^ (points/month)	0.521 (0.18, 0.913)	0.661 (0.331, 1.088)	0.387 (0.206, 0.839)	0.623 (0.343, 1.009)	0.449 (0.206, 0.888)	0.643 (0.338, 1.067)*
ALSFRS_R Score^	39 (31.5, 43)	37 (27.8, 41.3)	36 (32, 39.3)	35 (31, 38)	37 (32, 41)	36 (30.1, 40)
Diagnosis [n (%)]						
Definite ALS	3 (10.3%)	16 (21.6%)	9 (26.5%)	11 (36.7%)	12 (19%)	27 (26.0%)
Probable ALS	10 (34.5%)	37 (50%)	9 (26.5%)	12 (40%)	19 (30.2%)	49 (47.0%)
Possible ALS	12 (41.4%)	15 (20.3%)	16 (47%)	7 (23.3%)	28 (44.5%)	22 (21.2%)
Lab-Supported probable ALS	4 (13.8%)	6 (8.1%)	0	0	4 (6.3%)	6 (5.8%)

^: Median (IQR)

Comparison was made between the gender and within each cohort; Mann-Whitney U test or unpaired *t*-test was used where suitable.

*: p<0.05; **: p<0.01; ***: p<0.001; #: p=0.054; ##: p=0.057